Foreign investment control regulations: extension of COVID-19–related rules and new list and definition of strategic assets with a brief focus on the health industry
At the end of 2020, important regulatory measures regarding Italian foreign investment control regulations (known as the Golden Powers) were enacted: (i) a revised list and definition of critical and strategic assets in sectors relevant for the purposes of these regulations entered into force with effect from January 14, 2021, and (ii) the COVID-19 emergency rules providing for a temporary broadening of the scope of notification duties (which, among other things, also involve intra-EU transactions) have been extended through June 30, 2021.
Acquisitions of companies involved in the medical devices business fall under the Italian foreign investment control
More than 2 months ago the Italian Government issued certain measures with the purpose of expanding its power to veto or impose conditions on acquisitions of, or other transactions involving, Italian targets operating in certain strategic sectors.
Venture capital watch: an overview of 2019 investments
We recently attended the country-focused seminar Healthcare: Italy on the Move 2020 during the weeklong J.P. Morgan Annual Healthcare Conference in San Francisco.
Benefit companies: an overview from a corporate perspective
Italy was the first European country to issue a regulation on benefit companies (in Italian “società benefit”), importing the model from the US.
Diligent requirements for life sciences deals and earn-outs
Contingent payments (a.k.a. earn-outs in transactions among private companies, and contingent payment rights (CPRs) in transactions among listed companies) are a very common and valuable component of purchase price constructs in today’s life sciences and healthcare M&A deals.